- We are now the most active health investor in the UK.*
- Since joining forces with TenX, we have dramatically broadened our capabilities as a team and increased the scope of our investments. We now have a team of 10 investors and PhDs – including Joe Stringer (ex Head of Google Health UK) and Dr Pooja Sikka (EY Ventures and practicing GP) – only looking at health companies.
- We made a concerted effort to build our capabilities and network within biotech based on the scientific backgrounds of many of the team.
- We’ve invested in three new biotech companies in the last 12 months alongside some of the best biotech investors in the world.
- 70 of the most reputable health investors in the world met with our portfolio companies at an event we held in April 2021. This resulted in at least one term sheet and tens of valuable conversations.
- We completed research in a number of areas, driving thesis-led, high-conviction investments including the future of cannabinoids, neurotech and synthetic biology.
- US expansion and fundraising continues to be a large theme within the health portfolio with one in four of our health companies being head-quartered in the US, 50% of our portfolio having a material presence and 65% having US customers.
- We continue to invest across all stages but with a bias towards the earliest stages (Seed and Series A).
- A number of phenomenal portfolio milestones have been reached in the last 12 months including a plethora of FDA and CE approvals, Elvie’s $75m Series C, QuitGenius’ $64m Series B, Medisafe’s $30m Series C and Antidote’s $14m Series C.
